SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

Major difference between Donepezil and A-273 is the

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
cadno Member Profile
 
Followed By 0
Posts 26
Boards Moderated 0
Alias Born 08/25/17
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 12/15/2017 4:13:15 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 12/15/2017 4:11:28 PM
Annual Report (10-k) "Edgar (US Regulatory)" - 12/11/2017 5:17:35 PM
Anavex Life Sciences Reports Fiscal 2017 Financial Results And Provides Update On Therapeutic Programs "GlobeNewswire Inc." - 12/11/2017 7:00:00 AM
Anavex Life Sciences Reports Newly Published Data on Alzheimer's Disease Research Demonstrate the Neuroprotective Features of... "GlobeNewswire Inc." - 11/21/2017 7:00:00 AM
Anavex Life Sciences to Present at the 5th Annual Mental Health Parity Addiction Equity Act Business Roundtable in Washington... "GlobeNewswire Inc." - 11/8/2017 7:00:00 AM
Anavex Life Sciences Presents New Clinical Data of Investigational Alzheimer’s Disease Treatment ANAVEX®2-73 at 2017 Clini... "GlobeNewswire Inc." - 11/4/2017 3:30:00 PM
Greenbank Cap, Inc. (OTC Pink: GRNBF) Closes Private Placement as Shares Climb "InvestorsHub NewsWire" - 10/30/2017 7:00:00 AM
Anavex Life Sciences Announces Additional Data at The Michael J. Fox Foundation’s Parkinson's Disease Therapeutics Conferen... "GlobeNewswire Inc." - 10/30/2017 7:00:00 AM
Anavex Life Sciences Announces New Data Related to Multiple Sclerosis Presented at 7th ECTRIMS-ACTRIMS Meeting MSPARIS2017 "GlobeNewswire Inc." - 10/27/2017 8:52:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/26/2017 2:50:54 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/24/2017 12:06:59 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/19/2017 6:47:52 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/18/2017 9:47:41 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/16/2017 11:07:52 AM
Anavex Life Sciences Reports PK and PD Data from Phase 2a Trial of ANAVEX®2-73 in Mild-to-Moderate Alzheimer’s Disease Pat... "GlobeNewswire Inc." - 10/12/2017 7:00:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/6/2017 5:18:01 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/5/2017 5:57:37 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/2/2017 7:53:34 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/29/2017 2:33:03 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/26/2017 3:10:51 PM
Anavex Life Sciences to Present at the Ladenburg Thalmann 2017 Healthcare Conference "GlobeNewswire Inc." - 9/21/2017 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/20/2017 4:51:51 PM
Biotech's Recently Under the Microscope, Analyst Coverage "InvestorsHub NewsWire" - 9/20/2017 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/19/2017 1:59:44 PM
cadno   Friday, 10/13/17 04:58:30 AM
Re: Rubyred77 post# 124369
Post # of 134637 
Quote:
Major difference between Donepezil and A-273 is the side effects. If the two were hypothetically equal, just on less side effects, we would have a new SOC if p2/3 repeats its p2a/b results.

However, we all know Donepezil doesn't work for a year, more like a month or two before the decline starts again.

Plus, we don't know exactly HOW much a-273 does benefit, or as the naysayers say, if it benefits at all, the patient because the dosage isn't optimized across the board. Some need to understand that and not treat this data as "as good as it gets".

We are yet to see just how good a-273 works when given with the correct dosage.



I agree with all of that. "Work" is relative, but sure, it begins to decline after one month to a few months. However, the data we have for 2-73 shows similarly, apart from that uptick at 52 weeks which I don't put too much emphasis on statistically.

I agree on side effects, as I stated below, but the difference between a drug with equal efficacy with few side effects and a drug with a stable MMSE over two years with few side effects is night and day. It's the difference between a drug with real potential and a drug with paradigm shifting blockbuster potential.

I am aware the 2-73 dose is not optimized. I'm working with what is at hand, for the time being. What else is there? I certainly don't see this data as anything other than preliminary and is certainly not "as good as it gets," if that's what you're suggesting.

Re the optimized dosage, what dosage did they put them on for the extension after the 57 weeks? I've seen someone write that they put them all on optimized dosage, but I haven't seen that on the website.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist